Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-25T02:16:51.431Z Has data issue: false hasContentIssue false

24 - Treatment of co-occurring psychiatric and substance use disorders

from Part III - Specific treatments

Published online by Cambridge University Press:  12 May 2010

By
Douglas M. Ziedonis ,
Ed. Day ,
Erin L. O'Hea ,
Jonathan Krejci ,
Jeffrey A. Berman  and
David Smelson
Edited by
Peter Tyrer  and
Kenneth R. Silk
Douglas M. Ziedonis
Affiliation:
University of Massachusetts Memorial Medical Center Worcester, MA USA
Ed. Day
Affiliation:
Department of Psychiatry Queen Elizabeth Psychiatric Hospital Edgbaston Birmingham UK
Erin L. O'Hea
Affiliation:
Department of Psychology La Salle University Philadelphia, PA USA
Jonathan Krejci
Affiliation:
Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA
Jeffrey A. Berman
Affiliation:
Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons New Jersey, NJ USA
David Smelson
Affiliation:
Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA
Peter Tyrer
Affiliation:
Imperial College of Science, Technology and Medicine, London
Kenneth R. Silk
Affiliation:
University of Michigan, Ann Arbor
Get access

Summary

Editor's note

The co-morbidity of a concurrent substance use disorder and a non-substance major psychiatric disorder is quite common. Yet there is very little data available to inform the clinician as to what treatment(s) might be best for this particular group of patients with this particular set of substance abuse plus non-substance psychiatric co-morbidity. In general, the limited research available, consensus recommendations and clinical experiences all suggest that integrated treatment, i.e. treatment by the same group of providers that addresses both the substance misuse and the other major mental illness is most effective. However, there are exceptions to this rule and providers must be flexible and offer a combination of services regarding what works best in treating the mental disorder plus what works best in the treatment of the specific substance abuse disorder. While on the surface this appears to be logical and pragmatic, this kind of reasoning does not always work. For example, there is some evidence that lithium is less effective in people with bipolar disorder complicated by substance abuse than it is in bipolar disorder alone. Furthermore, some pharmacological agents used to treat some psychiatric disorders have an increased liability for abuse and dependency, suggesting greater caution in using these interventions when substance abuse is a comorbid issue. The most efficacious treatment approach is probably integrated multi-modal treatment which involves the same group of caregivers providing treatment to both the mental illness and the substance misuse disorder.

Type
Chapter
Information
Cambridge Textbook of Effective Treatments in Psychiatry , pp. 442 - 458
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abou-Saleh, M. T. (2004). Dual diagnosis: management within a psychosocial context. Advances in Psychiatric Treatment, 10, 352–60.Google Scholar
Albanese, M. J., Khantzian, E. J., Murphy, S. L.et al. (1994). Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry, 151(5), 780–1.Google Scholar
Albanese, M. J. (2001). Safety and efficacy of risperidone in substance abusers with psychosis. American Journal on Addictions, 10, 190–1.Google Scholar
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. Washington, DC: American Psychiatric Association.
Baker, A., Lewin, T., Reichler, H.et al. (2002). Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatrica Scandinavica, 106, 233–40.Google Scholar
Bakker, A., Balkom, A. J. & Dyck, R. (2000). Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. International Clinical Psychopharmacology, 15 (Suppl. 2). S25–30.Google Scholar
Ball, S. A. (1998). Manualized treatment for substance abusers with personality disorders: dual focus schema therapy. Addictive Behaviors, 23(6), 883–91.Google Scholar
Barlow, D. H. (2002). Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic, 2nd edn. New York: Guilford Press.
Barrowclough, C., Haddock, G., Tarrier, N.et al. (2001). Randomized controlled trial of motivational interviewing, cognitive behaviour therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158(10), 1706–13.Google Scholar
Beck, A. T., Wright, F. D., Newman, C. F. & Liese, B. S. (1993). Cognitive Therapy of Substance Abuse. New York: Guilford Press.
Bellack, A. S., Buchanan, R. W. & Gold, J. M. (2001). The American Psychiatric Association practice guidelines for schizophrenia: scientific base and relevance for behavior therapy. Behavior Therapy, 32(2), 283–308.Google Scholar
Bond, G. R., McDonel, E. C., Miller, L. D.et al. (1991). Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosocial Rehabilitation Journal, 15(2), 31–43.Google Scholar
Bowden, C. L. (2001). Clinical correlates of therapeutic response in bipolar disorder. Journal of Affective Disorders, 67(1–3), 257–65.Google Scholar
Bradizza, C. M. & Stasiewicz, P. R. (1997). Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. Journal of Substance Abuse Treatment, 14(2), 103–11.Google Scholar
Brady, K. T. (2001). Comorbid posttraumatic stress disorder and substance use disorders. Psychiatric Annals, 31(5), 313–19.Google Scholar
Brady, K. T. & Clary, C. M. (2003). Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Comprehensive Psychiatry, 44(5), 360–9.Google Scholar
Brady, K. T., Sonne, S. C., Anton, R.et al. (1995). Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. Journal of Clinical Psychiatry, 56(3), 118–21.Google Scholar
Brady, K. T., Dansky, B. S., Back, S. E.et al. (2001). Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. Journal of Substance Abuse Treatment, 21(1), 47–54.Google Scholar
Brady, K. T., Myrick, H., Henderson, S.et al. (2002). The use of divalproex in alcohol relapse prevention: a pilot study. Drug and Alcohol Dependence, 67, 323–30.Google Scholar
Brecher, M., Wang, B. W., Wong, H.et al. (1988). Phencyclidine and violence: clinical and legal issues. Journal of Clinical Psychopharmacology, 8, 398–401.Google Scholar
Broadnick, P. S. & Schmitz, J. M. (1997). Cocaine craving: an evaluation across treatment phases. Journal of Substance Abuse, 10(1), 9–17.Google Scholar
Brown, E. S., Nejtek, B. A., Perantie, D. C.et al. (2002). Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disorder, 4(6), 406–11.Google Scholar
Brunette, M. F., Drake, R. E., Woods, M.et al. (2001). A comparison of long-term and short-term residential treatment programs for dual diagnosis patients. Psychiatric Services, 52(4), 526–8.Google Scholar
Buckley, P. F. (1998). Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. Journal of Substance Abuse Treatment, 15, 113–16.Google Scholar
Buckley, P., Thompson, P., Way, L.et al. (1994a). Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151, 385–9.Google Scholar
Buckley, P., Thompson, P. A. & Way, L. (1944b). Meltzer, H. Y., Substance abuse and clozapine treatment. Journal of Clinical Psychiatry, 55 (Suppl. B), 114–16.Google Scholar
Budde, R. D. (1989). Cocaine abuse and violent death. American Journal of Drug and Alcohol Abuse, 15, 375–82.Google Scholar
Carey, K. B. (1995). Treatment of substance use disorders and schizophrenia. In Double Jeopardy: Chronic Mental Illness and Substance Use Disorders, ed. Lehman, A. F. & Dixon, L. B., pp. 85–108. Langhorne, PA: Harwood Academic Publishers/Gordon and Breach Science Publishers.
Carol, G., Smelson, D. A., Losonczy, M. F.et al. (2001) A preliminary investigation of cocaine craving among persons with and without Schizophrenia. Psychiatric Services, 52(8), 1029–31.Google Scholar
Chilcoat, H. D. & Breslau, N. (1988). Posttraumatic stress disorder and drug disorders: testing causal pathways. Archives of General Psychiatry, 55(10), 913–17.Google Scholar
Conley, R. R., Kelly, D. L. & Gale, E. A. (1998). Olanzapine response in treatment-refactory schizophrenic patients with a history of substance abuse. Schizophrenia Research, 33, 95–101.Google Scholar
Copello, A., Graham, H. & Birchwood, M. (2001). Evaluating substance misuse interventions in psychosis: the limitations of the RCT with ‘patient’ as the unit of analysis. Journal of Mental Health, 10(6), 585–7.Google Scholar
Cottler, L. B., Compton, W. M. 3rd., Mager, D.et al. (1992). Posttraumatic stress disorder among substance users from the general population. American Journal of Psychiatry, 149(5), 664–70.Google Scholar
Crumley, F. E. (1990). Substance abuse and adolescent suicidal behavior. Journal of the American Medical Association, 163, 3051–6.Google Scholar
Daley, D. C., Salloum, I. M. & Thase, M. E. (2003). Integrated treatment using a recovery-oriented approach. In Integrated Treatment for Mood and Substance Disorders, ed. Westmeyer, J. J., Weiss, R. D. & Ziedonis, D. M., pp. 68–89. Baltimore: Johns Hopkins University Press.
Dansky, B. S., Brady, K. T. & Saladin, M. E. (1998). Untreated symptoms of PTSD among cocaine-dependent individuals. Changes over time. Journal of Substance Abuse Treatment, 15(6), 499–504.Google Scholar
Dean, A. J., Bell, J., Mascord, D. J., Gordon, P.et al. (2002). A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. Journal of Affective Disorders, 72(1), 85–90.Google Scholar
Department of Health (2002). Mental Health Policy Implementation Guide: Dual Diagnosis Good Practice Guide. London: Department of Health.
DiClemente, C. C., Schlundt, D. & Gemmell, L. (2004). Readiness and stages of change in addiction treatment. American Journal on Addictions, 13(2), 103–19.Google Scholar
Dorpat, T. L. (1974). Drug automatism, barbiturate poisoning and suicide behavior. Archives of General Psychiatry, 31, 216–20.Google Scholar
Drake, R. E. & Mueser, K. T. (2000). Psychosocial approaches to dual diagnosis. Schizophrenia Bulletin, 26(1), 105–18.Google Scholar
Drake, R. E., Yovetich, N. A., Bebout, R. R.et al. (1997). Integrated treatment for dually diagnosed homeless adults. Journal of Nervous and Mental Disease, 185(5), 298–305.Google Scholar
Drake, R. E., McHugo, G. J., Clark, R. E.et al. (1998a). Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: A clinical trial. American Journal of Orthopsychiatry, 68, 201–15.Google Scholar
Drake, R. E., Mercer-McFadden, C., Mueser, K. T.et al. (1998b). Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin, 24(4), 589–608.Google Scholar
Drake, R. E., Xie, H., McHugo, G. J.et al. (2000). The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin, 26(2), 441–9.Google Scholar
Drake, R. E., Essock, S. M. & Shaner, A. (2001). Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services, 52(4), 469–76.Google Scholar
Fisher, M. S. & Bentley, K. J. (1996). Two group therapy models for clients with a dual diagnosis of substance abuse and personality disorder. Psychiatric Services, 47(11), 1244–50.Google Scholar
Fowler, I. L., Carr, V. J., Carr, N. T.et al. (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin, 24, 443–55.Google Scholar
Geller, B., Cooper, T. B., Sun, K.et al. (1998). Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry, 37(2), 171–8.Google Scholar
George, T. P. & Krystal, J. H. (2000). Comorbidity of psychiatric and substance abuse disorders. Current Opinion in Psychiatry, 13, 327–31.Google Scholar
Graham, H. L. (2004). Implementing integrated treatment for co-existing substance use and severe mental health problems in assertive outreach teams: training issues. Drug and Alcohol Review, 23, 463–70.Google Scholar
Graham, H. L., Maslin, J., Copello, A.et al. (2001). Drug and alcohol problems amongst individuals with severe mental health problems in an inner city area of the UK. Journal of Social Psychiatry and Psychiatric Epidemiology, 36, 448–55.Google Scholar
Graham, H. L., Copello, A., Birchwood, M.et al. (2003a). Cognitive-Behavioural Integrated Treatment (C-BIT): A Treatment Manual for Substance Misuse in People with Severe Mental Health Problems. Chichester: John Wiley.
Graham, H. L., Copello, A., Birchwood, M. J. et al. (2003b). The combined psychosis and substance use (COMPASS): an integrated shared-care approach. In Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery, ed. Graham, H. L., Copello, A., Birchwood, M. J.et al., pp. 106–20. Chichester: John Wiley.
Graham, H. L., Copello, A., Birchwood, M. J. et al. (2003c). Cognitive-behavioural integrated treatment approach for psychosis and problem substance use. In Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery, ed. Graham, H. L., Copello, A., Birchwood, M. J.et al., pp. 181–206. Chichester: John Wiley.
Graham, H. L., Copello, A., Birchwood, M. J.et al. (2006). A preliminary evaluation of integrated treatment for co-existing substance use and severe mental health problems: impact on teams and service users. Journal of Mental Health, 15(5), 577–91.Google Scholar
Green, A. I., Burgess, E. S., Dawson, R.et al. (2003). Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia Research, 60, 81–5.Google Scholar
Grice, D. E., Brady, K. T., Dustan, L. R.et al. (1995). Sexual and physical assault history and posttraumatic stress disorder in substance-dependent individuals. American Journal on Addictions, 4(4), 297–305.Google Scholar
Haddock, G., Barrowclough, C., Tarrier, N.et al. (2003). Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry, 183(5), 418–26.Google Scholar
Havassy, B. E., Shropshire, M. S. & Quigley, L. A. (2000). Effects of substance dependence on outcomes of patients in a randomized trial of two case management models. Psychiatric Services, 51(5), 639–44.Google Scholar
Hawton, K. (1987). Assessment of suicide risk. British Journal of Psychiatry, 150, 145–53.Google Scholar
Hellerstein, D. J. & Meehan, B. (1987). Outpatient group therapy for schizophrenic substance abusers. American Journal of Psychiatry, 144, 1337–9.Google Scholar
Hellerstein, D. J., Rosenthal, R. N. & Miner, C. R. (1995). A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. American Journal on Addictions, 4, 33–42.Google Scholar
Hellerstein, D. J., Rosenthal, R. N. & Miner, C. R. (2001). Integrating services for schizophrenia and substance use. Psychiatric Quarterly, 72(4), 291–306.Google Scholar
Ho, A. P., Tsuang, J. W., Liberman, R. P.et al. (1999). Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. American Journal of Psychiatry, 156(11), 1765–70.Google Scholar
Jacobsen, L. K., Southwick, S. M. & Kosten, T. R. (2001). Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. American Journal of Psychiatry, 158, 1184–90.Google Scholar
Jeffrey, D. P., Ley, A., McLaren, S.et al. (2000). Psychosocial treatment programmes for people with both severe mental illness and substance misuse (Cochrane Review). In The Cochrane Library. Chichester: John Wiley.
Jenike, M. A. (1997). Duration of antidepressant treatment. Journal of Geriatric Psychiatry and Neurology, 10(4), 247.Google Scholar
Jerrell, J. M. & Ridgely, M. S. (1995). Comparative effectiveness of three approaches to serving people with severe mental illness and substance use disorders. Journal of Nervous and Mental Disease, 183(9), 566–76.Google Scholar
Kavanagh, D. J., Mueser, K. T. & Baker, A. (2003a). Management of Comorbidity. In Comorbid Mental Disorders and Substance Use Disorders: Epidemiology, Prevention and Treatment, ed. Teesson, M. & Proudfoot, H.. Canberra, Australia: Commonwealth of Australia.
Kavanagh, D. J., Young, R., White, A. et al. (2003b). Start over and survive: a brief intervention for substance misuse in early psychosis. In Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery, ed. Graham, H. L., Copello, A., Birchwood, M. D.et al. Chichester: John Wiley.
Kelly, D., Gale, E. & Conley, R. (2003). Clozapine treatment in patients with prior substance abuse. Canadian Journal Psychiatry, 48(2), 111–14.Google Scholar
Kessler, R. C., Sonnega, A., Bromet, E.et al. (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry, 52(12), 1048–60.Google Scholar
Kessler, R. C., Nelson, C. B., McGonagle, K. A.et al. (1996). Comorbidity of DSM-III–R major depressive disorder in the general population: results from the US National Comorbidity Survey. British Journal of Psychiatry, 168(Suppl. 30), 17–30.Google Scholar
Kofoed, L., Friedman, M. J. & Peck, R. (1993). Alcoholism and drug abuse in patients with PTSD. Psychiatry Quarterly, 64(2), 151–71.Google Scholar
Kosten, T. R., Morgan, C. M., Falcione, J.et al. (1992). Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Archives of General Psychiatry, 49, 894–8.Google Scholar
Kosten, T. R., Brady, K. T., George, T. P.et al. (2003). Risperidone for substance dependent psychotic patients. CPDD Scientific Meeting Abstracts.Google Scholar
Kranzler, H. R., Burleson, J. A., Korner, P.et al. (1995). Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry, 152(3), 391–7.Google Scholar
Krausz, M., Haasen, C., Mass, R.et al. (1996). Harmful use of psychotropic substances by schizophrenics: coincidence, patterns of use and motivation. European Addiction Research, 2, 11–16.Google Scholar
Langevin, R., Paitich, D., Orchard, B.et al. (1982) The role of alcohol, drugs, suicide attempts and situational strains in homicide committed by offenders seen for psychiatric assessment: a controlled study. Acta Psychiatrica Scandinavica, 66, 229–42.Google Scholar
Lee, M. L., Dickson, R. A., Campbell, M.et al. (1998). Clozapine and substance abuse in patients with schizophrenia. Canadian Journal of Psychiatry, 43, 855–6.Google Scholar
Lehman, A. F., Herron, J. D., Schwartz, R. P.et al. (1993). Rehabilitation for adults with severe mental illness and substance use disorders. A clinical trial. Journal of Nervous and Mental Disease, 181(2), 86–90.Google Scholar
Leskin, G. A. & Sheikh, J. I. (2001). Lifetime trauma history and panic disorder: findings from the National Comorbidity Survey. Journal of Anxiety Disorders, 16(6), 599–603.Google Scholar
Linehan, M. M., Schmidt, H. 3rd., Dimeff, L. A.et al. (1999). Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. American Journal on Addictions, 8(4), 279–92.Google Scholar
Lingford-Hughes, A. R., Welch, S. & Nutt, D. J. (2004). Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association of Pharmacology. Journal of Psychopharmacology, 18(3), 293–335.Google Scholar
Linnoila, M. I. (1989). Anxiety and alcoholism. Journal of Clinical Psychiatry, 50, 26–9.Google Scholar
Liskow, B. I. & Goodwin, D. (1987). Pharmacological treatment of alcohol intoxication withdrawal and dependence: a critical review. Journal of Studies on Alcohol, 48, 356–70.Google Scholar
Littrell, K. H., Petty, R. G., Hilligoss, N. M.et al. (2001). Olanzapine treatment for patients with schizophrenia and substance abuse. Journal of Substance Abuse Treatment, 21, 217–21.Google Scholar
Luisada, P. V. (1978). The phencyclidine psychosis: phenomenology and treatment. NIDA Research Monograph, 21, 241–53.Google Scholar
Mackenzie, A., Funderburk, F. R. & Allen, R. P. (1999). Sleep, anxiety, and depression in abstinent and drinking alcoholics. Substance Use Misuse, 34(3), 347–61.Google Scholar
Marcus, P. & Snyder, R. (1995). Reduction of comorbid substance abuse with clozapine. American Journal of Psychiatry, 152, 959.Google Scholar
Martino, S., Carroll, K. M., O'Malley, S. S.et al. (2000). Motivational interviewing with psychiatrically ill substance abusing patients. American Journal on Addictions, 9(1), 88–91.Google Scholar
Martino, S., Carroll, K., Kostas, D.et al. (2002). Dual diagnosis motivational interviewing: a modification of motivational interviewing for substance-abusing patients with psychotic disorders. Journal of Substance Abuse Treatment, 23(4), 297–308.Google Scholar
Maslin, J. (2003). Substance misuse in psychosis: contextual issues. In Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery, ed. Graham, H. L., Copello, A., Birchwood, M. J.et al., pp. 3–23. Chichester, UK: John Wiley.
Mason, B. J., Kocsis, J. H., Ritvo, E. C.et al. (1996). A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. Journal of the American Medical Association, 275(10), 761–7.Google Scholar
Maxwell, S. & Shinderman, M. S. (2000). Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. Journal of Addictive Diseases, 19(3), 61–9.Google Scholar
McLellan, A. T. & Hunkeler, E. (1998). Patient satisfaction and outcomes in alcohol and drug abuse treatment. Psychiatric Services, 49(5), 573–5.Google Scholar
Meltzer, H. Y., Alphs, L., Green, A. I.et al. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry, 60(1), 82–91.Google Scholar
Menezes, P. R., Johnson, S., Thornicroft, G.et al. (1996). Drug and alcohol problems among individuals with severe mental illnesses in south London. British Journal of Psychiatry, 168, 612–19.Google Scholar
Mercer-McFadden, C., Drake, R. E., Brown, N. B.et al. (1997). The community support program demonstrations of services for young adults with severe mental illness and substance use disorders, 1987–1991. Psychiatric Rehabilitation Journal, 20(3), 13–24.Google Scholar
Miller, W. R., Zweben, A., DiClemente, C. C.et al. (1995) Motivational Enhancement Therapy Manual. Rockville, MD: US Department of Health and Human Services.
Minkoff, K. (1989). An integrated treatment model for dual diagnosis of psychosis and addiction. Hospital and Community Psychiatry, 40(10), 1031–6.Google Scholar
Mueser, K. T. & Drake, R. E. (2003). Integrated dual disorder treatment in New Hampshire (USA). In Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery, ed. Graham, H. L., Copello, A., Birchwood, M. J.et al. Chichester, UK: John Wiley.
Mueser, K. T., Nishith, P., Tracy, J. I.et al. (1995). Expectations and motives for substance use in schizophrenia. Psychiatric Clinics of North America, 21(3), 367–78.Google Scholar
Mueser, K. T., Yarnold, P. R., Rosenberg, S. D.et al. (2000). Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates and subgroups. Schizophrenia Bulletin, 26, 179–92.Google Scholar
Murphy, G. E. (1988). Suicide and substance abuse. Archives of General Psychiatry, 45, 593–4.Google Scholar
Nace, E. P. (1990). Substance abuse and personality disorder. Journal of Chemical Dependency Treatment, 3(2), 183–98.Google Scholar
Najavits, L. M., Weiss, R. D., Shaw, S. R.et al. (1998). Seeking safety: outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. Journal of Traumatic Stress, 11(3), 437–56.Google Scholar
Najavits, L. M., Runkel, R., Neuner, C.et al. (2003). Rates and symptoms of PTSD among cocaine-dependent patients. Journal of Studies on Alcohol, 64(5), 601–6.Google Scholar
National Institute for Clinical Excellence (2002). Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: National Institute for Clinical Excellence.
Noordsy, D. L. & Green, A. I. (2003). Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current Psychiatry Reports, 5, 340–6.Google Scholar
Nunes, E. V. & Quitkin, F. M. (1997). Treatment of depression in drug-dependent patients: effects on mood and drug use. In Treatment of Drug-Dependent Individuals with Comorbid Mental Disorders, ed. Onken, L. S., Blaine, J. D., Genser, S.et al., pp. 61–85. National Institute on Drug Abuse: Rockville, MD.
Nunes, E. V., McGrath, P. J., Quitkin, F. M.et al. (1995). Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug and Alcohol Dependence, 39(3), 185–95.Google Scholar
Nunes, E. V., Quitkin, F. M., Donovan, S. J.et al. (1998). Imipramine treatment of opiate-dependent patients with depressive disorders. Archives of General Psychiatry, 55, 153–160.Google Scholar
Nunes, E. V., McGrath, P. J., Wager, S.et al. (1990). Lithium treatment for cocaine abusers with bipolar spectrum disorder. American Journal of Psychiatry, 147(5), 655–7.Google Scholar
Nunes, E. & Levin, F. R. (2004). Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. Journal of the American Medical Association, 291, 1887–96.Google Scholar
O'Connell, R. A., Mayo, J. A. & Flatlow, L. (1991). Outcome of bipolar disorder on long-term treatment with lithium. British Journal of Psychiatry, 159, 123–9.Google Scholar
O'Hea, E. L., Dutton, G. & Boudreaux, E. D. (2002). Identifying and managing patients with panic disorder in the emergency. Emergency Psychiatry, 8, 21–6.Google Scholar
Petrakis, I., Carroll, K. M., Nich, C.et al. (1998). Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug and Alcohol Dependence, 50, 221–6.Google Scholar
Regier, D. A., Farmer, M. E., Rae, D. S.et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. Journal of the American Medical Association, 264, 2511–18.Google Scholar
Roberts, L., Shaner, A. & Eckman, T. A. (1999). Overcoming Addictions: Skills Training for People With Schizophrenia. New York: W. W. Norton.
Ross, H. E., Glaser, F. B. & Germanson, T. (1988). The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Archives of General Psychiatry, 45, 1023–31.Google Scholar
Roy, A. (1998). Placebo-controlled study of sertaline in depressed recently abstinent alcoholics. Biological Psychiatry, 44(7), 633–7.Google Scholar
Sajatovic, M., Mullen, J. A. & Sweitzer, D. E. (2002). Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. Journal of Clinical Psychiatry, 63(12), 1156–63.Google Scholar
Salloum, I. M. & Thase, M. E. (2000). Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disorders, 2, 269–80.Google Scholar
SAMHSA (2003). SAMHSA report to congress on the prevention and treatment of co-occurring substance abuse disorders and mental disorders. Washington DC: US Department of Health and Human Services.
Sattar, S. P., Grant, K., Bhatia, S.et al. (2003). Potential use of olanzapine in treatment of substance dependence disorders. Journal of Clinical Psychopharmacology, 23(4), 413–15.Google Scholar
Shaner, A., Eckman, T., Roberts, L. J.et al. (2003). Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. Psychiatric Services, 54(9), 1287–9.Google Scholar
Siris, S. G. (1990). Pharmacological treatment of substance-abusing schizophrenic patients. Schizophrenia Bulletin, 16, 111–22.Google Scholar
Smelson, D. A., Roy, A., Roy, M.et al. (2001). Electroretinogram and cue-elicited craving in withdrawn cocaine-dependent patients: a replication. American Journal of Drug and Alcohol Abuse, 27(2), 391–7.Google Scholar
Smelson, D. A., Losonczy, M., Kaune, M.et al. (2002a). Risperidone decreases cue-elicited craving and relapses in withdrawn cocaine-dependent schizophrenics. Schizophrenia Research, 53, 160.Google Scholar
Smelson, D. A., Losonczy, M. F., Davis, C. W.et al. (2002b). Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry, 47, 671–5.Google Scholar
Smelson, D. A., Davis, C., Eisenstein, N.et al. (2003). Neuropsychological functioning among individuals with schizophrenia and cocaine dependence. Journal of Substance Abuse Treatment, 24, 75–9.Google Scholar
Smelson, D. A., Williams, J., Ziedonis, D.et al. (2004). A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. Journal of Substance Abuse Treatment 27, 45–9.Google Scholar
Stein, M. D., Bishop, S., Lassor, J. A.et al. (2004). Sleep disturbances among methadone maintained patients. Journal of Substance Abuse Treatment, 26(3), 175–80.Google Scholar
Swanson, A. J., Pantalon, M. V. & Cohen, K. R. (1999). Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. Journal of Nervous and Mental Disease, 187(10), 630–5.Google Scholar
Teesson, M. & Proudfoot, H. (2003). Comorbid Mental Disorders and Substance Use Disorders: Epidemiology, Prevention and Treatment. Canberra, Australia: Commonwealth of Australia.
Timko, C. & Sempel, J. M. (2004). Short-term outcomes of matching dual diagnosis patients' symptom severity to treatment intensity. Journal of Substance Abuse Treatment, 26, 209–18.Google Scholar
Triffleman, E., Carroll, K. & Kellogg, S. (1999). Substance dependence posttraumatic stress disorder therapy. An integrated cognitive-behavioral approach. Journal of Substance Abuse Treatment, 17, 3–14.Google Scholar
Tsuang, J. W., Eckman, T. E., Shaner, A.et al. (1999). Clozapine for substance-abusing schizophrenic patients. American Journal of Psychiatry, 156(7), 1119–20.Google Scholar
Tsuang, J. W., Eckman, T., Marder, S.et al. (2002). Can risperidone reduce cocaine use in substance abusing schizophrenic patients? Journal of Clinical Psychopharmacology, 22, 629–30.Google Scholar
Ursano, R. J., Bell, C., Eth, S.et al. (2004).Work Group on ASD and PTSD. Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Journal of Psychiatry, 161(11 Suppl), 3–31.Google Scholar
Weiss, R. D., Greenfield, S. F., Najavits, L. M.et al. (1998). Medication compliance among patients with bipolar disorder and substance use disorder. Journal of Clinical Psychiatry, 59, 172–4.Google Scholar
Weiss, R. D., Griffin, M. L., Greenfield, S. F.et al. (2000). Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. Journal of Clinical Psychiatry, 61(5), 361–7.Google Scholar
Weiss, R. D., Greenfield, S. F. & O'Leary, G. (2003). Relapse prevention for patients with bipolar and substance use disorders. In Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery, ed. Graham, H. L., Copello, A., Birchwood, M. J.et al. Chichester: John Wiley.
Westermeyer, J., Yargic, I. & Thuras, P. (2004). Michigan assessment-screening test for alcohol and drugs (MAST/AD): evaluation in a clinical sample. American Journal on Addictions, 13(2), 151–62.Google Scholar
Ziedonis, D. M. & Stern, R. (2001). Dual recovery therapy for schizophrenia and substance abuse. Psychiatric Annals, 31(4), 255–64.Google Scholar
Ziedonis, D. & Williams, J. (2003) Management of smoking in people with psychiatric disorders. Current Opinion in Psychiatry, 16(3), 305–15.Google Scholar
Ziedonis, D., Richardson, T., Lee, E.et al. (1992). Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacology Bulletin, 28(3), 309–14.Google Scholar
Ziedonis, D. M., Rayford, B. S., Bryant, K.et al. (1994). Psychiatric comorbidity in White and African-American cocaine addicts seeking substance abuse treatment. Hospital and Community Psychiatry, 45, 43–9.Google Scholar
Ziedonis, D. M. & Fisher, W. (1996). Motivation based assessment and treatment of substance abuse in patients with schizophrenia. In The Hatherleigh Guide to Treating Substance Abuse (Part II), pp. 269–87. New York, NY: Hatherleigh Press.
Zimmerman, M., Sheeran, P., Chelminski, I.et al. (2004). Screening for psychiatric disorders in outpatients with DSM-IV substance use disorders. Journal of Substance Abuse Treatment, 26(3), 181–8.Google Scholar
Zimmet, S. V., Strous, R. D., Burgess, E. S.et al. (2000). Effects of Clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. Journal of Clinical Psychopharmacology, 20, 94–8.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Treatment of co-occurring psychiatric and substance use disorders
    • By Douglas M. Ziedonis, University of Massachusetts Memorial Medical Center Worcester, MA USA, Ed. Day, Department of Psychiatry Queen Elizabeth Psychiatric Hospital Edgbaston Birmingham UK, Erin L. O'Hea, Department of Psychology La Salle University Philadelphia, PA USA, Jonathan Krejci, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA, Jeffrey A. Berman, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons New Jersey, NJ USA, David Smelson, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA
  • Edited by Peter Tyrer, Imperial College of Science, Technology and Medicine, London, Kenneth R. Silk, University of Michigan, Ann Arbor
  • Book: Cambridge Textbook of Effective Treatments in Psychiatry
  • Online publication: 12 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544392.026
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Treatment of co-occurring psychiatric and substance use disorders
    • By Douglas M. Ziedonis, University of Massachusetts Memorial Medical Center Worcester, MA USA, Ed. Day, Department of Psychiatry Queen Elizabeth Psychiatric Hospital Edgbaston Birmingham UK, Erin L. O'Hea, Department of Psychology La Salle University Philadelphia, PA USA, Jonathan Krejci, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA, Jeffrey A. Berman, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons New Jersey, NJ USA, David Smelson, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA
  • Edited by Peter Tyrer, Imperial College of Science, Technology and Medicine, London, Kenneth R. Silk, University of Michigan, Ann Arbor
  • Book: Cambridge Textbook of Effective Treatments in Psychiatry
  • Online publication: 12 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544392.026
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Treatment of co-occurring psychiatric and substance use disorders
    • By Douglas M. Ziedonis, University of Massachusetts Memorial Medical Center Worcester, MA USA, Ed. Day, Department of Psychiatry Queen Elizabeth Psychiatric Hospital Edgbaston Birmingham UK, Erin L. O'Hea, Department of Psychology La Salle University Philadelphia, PA USA, Jonathan Krejci, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA, Jeffrey A. Berman, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons New Jersey, NJ USA, David Smelson, Department of Psychiatry Robert Wood Johnson Medical School VA Health Care System Lyons, NJ USA
  • Edited by Peter Tyrer, Imperial College of Science, Technology and Medicine, London, Kenneth R. Silk, University of Michigan, Ann Arbor
  • Book: Cambridge Textbook of Effective Treatments in Psychiatry
  • Online publication: 12 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544392.026
Available formats
×